Open Access

Erratum to: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

  • Carlotta Nannini1Email author,
  • Colin P West2, 3,
  • Patricia J Erwin4 and
  • Eric L Matteson1
Arthritis Research & Therapy200911:408

https://doi.org/10.1186/ar2679

Published: 30 April 2009

The original article was published in Arthritis Research & Therapy 2008 10:R124

It has been brought to our attention that Figure 2b in our recently published paper [1] contains an error. Specifically, we inadvertently entered -6.4 rather than +6.4 for the Nadaskevich paper [2] reported in Figure 2b. Recalculation of the summary estimate for diffusing lung capacity of carbon monoxide (DLCO) in this figure revealed a summary mean difference of 3.74, with 95% confidence interval (0.09 to 7.40). This effect is now statistically significant, although the overall conclusion of our meta-analysis, that cyclophosphamide treatment did not result in clinically significant improvement of pulmonary function, is unchanged by this recalculation, as the improvement remains less than the predefined criterion of 10%. The corrected figure 2b is given here as Figure 1.
Figure 1

Forest plot of the overall meta-analysis result in the randomized clinical trials. Comparison of the diffusing capacity for carbon monoxide (DLCO) at 12 months for patients with scleroderma lung disease treated with cyclophosphamide versus a control group. See Table 2 [1] for study details. RCT, randomized clinical trial; SE, standard error; CI, confidence interval; Chi2, chi-squared; df, degree of freedom; I2, I-squared; Z, Z value; Mean difference, weighted mean difference; Random, random-effects.

Notes

Declarations

Authors’ Affiliations

(1)
Division of Rheumatology, Mayo Clinic College of Medicine
(2)
Division of General Internal Medicine, Mayo Clinic College of Medicine
(3)
Division of Biostatistics, Mayo Clinic College of Medicine
(4)
Medical Library, Mayo Clinic College of Medicine

References

  1. Nannini C, West CP, Erwin PJ, Matteson EL: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008, 10: R124-10.1186/ar2534.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Nadashkevich O, Davis P, Fritzler M, Kovalenko W: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006, 25: 205-212. 10.1007/s10067-005-1157-y.View ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2009

Advertisement